Denmark’s VentriJect Secures €1.7 Million Funding

The round led mainly by existing backers follows earlier raises in 2021 and 2024. Participants include the Export and Investment Fund of Denmark (EIFO), TechStation | HardTech Innovation Hub, Investo Capital, and private investor Carsten Stendevad, former CEO of one of Denmark’s largest pension funds.

CEO Mikkel Kristiansen shared with EU-Startups: “We are incredibly proud of the continued great trust we have from our existing investors, as well as from the new investors who have come on board. There has been a lot of interest in us as a company over the past year – from potential customers, partners, and investors alike. We have created a product that really resonates with the time we are in, where there’s an increased focus on preventative health and on living healthier and longer.

“We can see this in our European markets, and we are also experiencing great interest from the American market. Therefore, the next period will be really exciting for us as a company, and this capital injection will help us intensify the journey we are on right now.”

Read Also - Minders Acquires Dise For Strengthen Telegram’s B2B Sales Infrastructure

VentriJect, a spinout from Aalborg University in Denmark, was founded in 2018 and brought its first product to market by 2021. With applications in both medical and fitness sectors, the technology has fueled rapid EU-wide expansion since its major funding round in 2021.

Its flagship product, the Seismofit, is a CE-marked medical device that uses seismocardiography to detect chest wall movements from heart vibrations. In under three minutes — without requiring exercise — the system estimates a person’s cardiorespiratory fitness (VO₂ max). Paired with VentriJect’s algorithm, the results are delivered directly to users via the VentriJect app.

Anders Throup-Jensen from EIFO said “We are very pleased to have invested in VentriJect’s latest investment round. We have been an investor in the company since 2021 and believe in a strong future for the company as a market leader in VO2 Max measurements. We have been very impressed by the team and their ability to open new markets. I look forward to continuing to work with the management team as we grow our sales in the EU and the US.”

CEO Kristiansen believes VentriJect is well-positioned to ride the wave of growth in the Nordic startup scene. While Denmark is already known for producing innovative tech companies, he notes a rising focus on healthtech.

As an example, he points to the €48 million investment by Novo Holdings and the Export and Investment Fund of Denmark (EIFO) into the HealthCap IX fund, dedicated to Nordic medical technology — a sign that VC interest in the sector is accelerating.

VentriJect currently serves customers in multiple European markets and has recently secured distributors in Denmark, the Netherlands, Sweden, Switzerland, and the UK.

The company is also in advanced talks with several healthcare providers across Europe and is exploring entry into the US — a move that would open access to over 55,000 health clubs and the world’s largest healthcare market.

About VentriJect

VentriJect, a 2018 spin-out from Aalborg University, is revolutionising VO₂ max testing with Seismofit — a patented, clinically validated device delivering accurate results in under three minutes without exercise or specialist training. This game-changing approach makes cardiorespiratory fitness assessment faster, easier, and more accessible for patients and healthcare providers.